OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has shown promising results in patients with severe aortic stenosis (AS) at high risk for conventional heart surgery. The safety and efficacy of transapical aortic valve implantation using the JenaValve™, a secondgeneration TAVI device, were evaluated. The system consists of a tested porcine root valve mounted on a nitinol stent with feelerguided positioning and clip fixation on the diseased leaflets.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has become a routine treatment option for severe aortic stenosis (AS) in patients at high risk for surgical aortic valve replacement (AVR) [1] [2] [3] [4] [5] . To date, two TAVI systems have received CE-mark approval and are currently commercially available: the self-expanding Medtronic CoreValve™ (Medtronic Inc., St. Paul, MN, USA) and the balloon-expandable Edwards Sapien XT™ (Edwards Lifesciences Inc., Irvine, CA, USA) system. More than 15 000 TAVI procedures have been performed worldwide to date. The transapical approach has been evaluated in clinical studies since 2004, using the Edwards Sapien™ valve to establish a TAVI technique that is independent of peripheral vascular status. Since 2008, the Edwards Sapien™ device has been the only commercially available valve approved for transapical TAVI. Major limitations of this device relate to the need for rapid procedural pacing and the limited capability of repositioning.
As a second-generation device, the JenaValve™ system ( JenaValve Technology GmbH, Munich, Germany) features anatomically aligned positioning without the need for rapid pacing during implantation. During the first step of deployment, the valve is fully repositionable. The JenaValve™ consists of a porcine root valve mounted on a low-profile self-expanding nitinol stent. In contrast to devices expanding within the aortic annulus, the JenaValve™ relies on an active clip fixation on the native aortic valve leaflets. Coronary occlusion due to obstruction by leaflets is prevented. The device underwent successful animal testing [6] and a first-in-man implantation series [7] . Here, we report on the 30-day results of the JenaValve™ pivotal study for CE-mark approval conducted in seven German centres.
MATERIALS AND METHODS

Patients
Between October 2010 and July 2011, 73 patients were enrolled in the trial, six patients were excluded; five due to screening failures and one withdrew consent (Fig. 1) . Surgical risk was assessed using the logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) [8] . Society of Thoracic Surgeons Predicted Risk of Mortality score calculation was not part of the study protocol.
Inclusion criteria involved patients with symptomatic AS with an aortic valve area of ≤1.0 cm² and/or a mean transvalvular pressure gradient of ≥40 mmHg and/or a peak velocity of >4 m/s, an aortic annulus diameter between 21 and 26.9 mm, age ≥75 years, New York Heart Association (NYHA) class ≥II and a logistic EuroSCORE of ≥20%. Preprocedural transthoracic echocardiography (TTE) and transoesophageal echocardiography (TEE) were used for evaluation. Preprocedural imaging of the aorta and the femoral vessels was performed and analysed for aortic annulus diameters, straight length of the ascending aorta as measured from annulus to begin of curvature (≥65 mm) and distance between valve level and coronary ostia (≥8 mm).
All participating centres had clinical experience with transapical TAVI. The study was approved by the local ethics committees of the participating sites and the German competent authority (Bundesinstitut für Arzneimittel und Medizinprodukte). All patients provided written informed consent in accordance with the principles of the Declaration of Helsinki.
Study device
The JenaValve™ AVR system is designed as a tri-leaflet porcine root tissue valve. It is attached to a low profile nitinol stent with flexible stent posts supporting the valve leaflets and positioning feelers for accurate placement of the prosthesis with regard to the native valve leaflets (Fig. 2) . The valve prosthesis is manufactured in three different sizes (23-, 25-and 27-mm) for implantation in native aortic annuli ranging from 21 to 27 mm in diameter. A sheathless 32Fr delivery catheter is utilized for the three-step deployment procedure.
Valve implantation
Implantation was performed in seven institutions in Germany (University Heart Center, Hamburg, 27 patients; Heart Center, Leipzig, 19 patients; University Hospital, Jena, 11 patients; University Heart Center, Erlangen, 9 patients; Kerckhoff Clinic, Bad Nauheim, 5 patients; German Heart Center, Munich, 1 patient and Heart Center, Bad Oeynhausen, 1 patient). All procedures were performed under general anaesthesia in hybrid operating rooms equipped for cardiologic interventions and cardiac operations. TEE was performed throughout the procedure. Transapical access was gained via left lateral minithoracotomy in the fifth or sixth intercostal space. Pleura and pericardium were opened and the apex was exposed using pericardial sutures. Two pledgeted purse-string sutures were placed apically and an epicardial pacemaker wire was positioned and tested for proper performance. After femoral artery puncture and the introduction of a 6F sheath, a pigtail catheter was advanced into the ascending aorta. A bolus of 5000-10 000 international units of heparin was administered intravenously in a weight-dependent manner to achieve an activated clotting time of >250 s.
After the apical puncture, a soft guidewire was advanced into the descending aorta and subsequently exchanged for a stiff guidewire. A 14F sheath was carefully introduced into the left ventricle followed by a balloon catheter. Pre-procedural balloonvalvuloplasty of the native valve was performed under rapid pacing. Sizing of the balloon was dependent on the size of the aortic annulus and the degree of calcification. After removal of the balloon, the delivery catheter with the loaded valve prosthesis was introduced over the wire into the left ventricle and advanced through the native valve into the ascending aorta. Complete valve deployment was performed under fluoroscopic control under beating heart conditions without rapid pacing. First, the positioning feelers were released and checked for correct orientation. By pulling back the catheter, the positioning feelers were placed deep into the sinuses of the native aortic root. Correct positioning was controlled by two fluoroscopic views in different angulations. Second, the lower stent part was released thereby clipping and attaching the native leaflets to the device simultaneously unfolding the porcine valve. Third, the upper stent part was opened and the device was completely deployed (Fig. 3 ). TEE and aortography were performed to reconfirm coronary flow, paravalvular and central regurgitation, transvalvular pressure gradients and effective valve opening area. In case of elevated transvalvular gradients or significant paravalvular leakage, re-balloon-valvuloplasty of the JenaValve™ was performed. The delivery catheter was removed and ventricular haemostasis was achieved with the purse-string sutures. After the chest tube insertion surgical closure of the thoracotomy was carried out. Patients were treated with daily ASA 100 mg lifelong and 75 mg clopidogrel for at least 6 months post-procedure.
Follow-up
Patients underwent follow-up examinations including TTE and NYHA functional class status at the time of procedure, at discharge from hospital and at 30 days. Additional follow-up visits are scheduled for 3, 6 and 12 months. In order to generate accurate baseline and follow-up data comparisons, all echocardiographic data are reported from TTE. Adverse events were collected throughout the study.
Statistical analyses and data management
Continuous variables are expressed as mean ± standard deviation. Categorical variables are presented as numbers and proportions (%). Two-sided 95% confidence intervals were calculated based on the binomial distribution. Changes in continuous variables between baseline and at 30 days were assessed using paired Student's t-test. Categorical variables were compared with the continuity-corrected χ 2 test for dependent samples. Statistical analyses were performed using statistical analysis software (SAS 9.2). A two-sided P < 0.05 was considered statistically significant. Data were monitored by an independent clinical research organization, an independent Data Safety Monitoring Board and major cardiac and cerebrovascular events adjudicated by an independent medical reviewer. The statistical analysis was performed by an independent statistician. All authors had full access to the complete data set and take responsibility for its integrity. All authors have read and agreed to the manuscript as written. 
RESULTS
Patients
Sixty-seven patients (35 men 32 women; mean age 83.1 ± 3.9 years) underwent TAVI with the JenaValve™ prosthesis. All patients suffered from severe symptomatic aortic valve stenosis. NYHA functional class III was present in the majority of patients (74.6%), class IV in 16.4% and class II in 9.0% of patients. Mean left ventricular ejection fraction (LVEF) was 54.1 ± 10.6%. Mean logistic EuroSCORE was 28.4 ± 6.5%. Demographic and baseline characteristics including comorbidities are listed in Table 1 .
Procedural results
Transapical implantation of the JenaValve™ prosthesis was successful in 60 of 67 patients ( procedural success rate 89.6%). Mean implantation time (defined from time of insertion until the time of removal of the JenaValve™ delivery system) was 8.9 ± 6.9 min.
Conversion to surgical AVR due to valve dislocation was necessary in four patients (6%). Three patients recovered and were alive at 30-day follow-up, one died of non-cardiac cause on Day 6 post-procedure. Dislocations were caused by incorrect valve positioning (n = 2), bicuspid anatomy (n = 1) and difficulties with manipulation of the delivery catheter (n = 2). As a consequence, the design of the delivery catheter was changed to a more flexible housing simplifying delivery catheter removal through the valve prosthesis after deployment. One patient developed severe paravalvular regurgitation after supra-annular placement of the study valve and was treated with a successful transapical valve-in-valve implantation of a 26-mm Edwards Sapien prosthesis. Another patient underwent successful transapical valve-in-valve implantations with a 29-mm Edwards Sapien prosthesis after supra-annular migration of the JenaValve™ prostheses post-release. Both patients were alive and well at 30 days. It was not possible to deliver the JenaValve™ prosthesis to the correct annular position in one patient due to unsuitable (non-apical) ventricular access location. As per protocol, this patient was withdrawn from the study after discharge since the patient did not receive the study device.
In successfully treated patients, transvalvular pressure gradients significantly decreased from a mean of 40.6 ± 15.9 mmHg pre- procedural to 10.0 ± 7.2 mmHg post-procedural (P < 0.0001). The effective orifice area (EOA) was increased from a mean of 0.7 ± 0.2-1.7 ± 0.6 cm² (P < 0.0001). were not obstructed in any of the procedures. Severe apical bleeding requiring cardiopulmonary bypass was necessary in two patients (3.0%). Both patients were initially successfully weaned from cardiopulmonary bypass; however, in one patient further haemodynamic support was required. During recannulation, a retrograde dissection of the descending aorta occurred leading to the patient's death. In one patient insertion of the diagnostic catheter led to rupture of the femoral artery and required surgical intervention. Procedural outcomes and characteristics are shown in Table 2 , echocardiographic outcomes in Fig. 4 . eight patients (Table 3) ; two of these patients developed new AV block already after balloon valvuloplasty before implantation of the JenaValve™ prosthesis and two already showed sick sinus syndrome and LBBB before the procedure.
Follow-up at 30 days
Patients were discharged from hospital after 10 ± 7 days (range 4-31 days). NYHA Functional Class improved significantly 30 days after valve implantation. The majority of patients (57.1%) presented with NYHA class I or II (7.1% NYHA class I, 50.0% NYHA class II), 35.7 with class III and 7.1% with NYHA class IV (Fig. 5) .
DISCUSSION
TAVI has already become the treatment of choice in patients with severe AS at high risk for surgical AVR in many European countries and has proven superior results and better survival compared with medical treatment alone [9] . The proportion of elderly patients with significant comorbidities who are either not referred for surgical AVR or declined by surgeons can be as high as 30% [10] . Due to the demographic development in western countries towards an aging population, a growing demand for less invasive treatment of AS can be anticipated.
The Medtronic CoreValve™ and the Edwards Sapien™ devices are currently the only two prostheses commercially available for TAVI. Design, technical differences and results have been previously described [11] [12] [13] .
Retrograde transfemoral or transsubclavian TAVI is limited by the degree of calcification of the access vessels and the aorta and aortic root. In contrast, transapical TAVI can be safely performed in almost every patient as long as the apex is not diseased. The minimally invasive procedure can be performed through a very small lateral thoracotomy thereby further reducing the surgical trauma. Currently, only the Edwards Sapien prosthesis is approved for transapical TAVI.
For the very first series of transapical Edwards Sapien™ implantations, Webb et al. [13] and Walther et al. [14] reported 30-day mortality rates of 18.2 and 13.6%. Mortality decreased as a function of the learning curve and recently Walther et al. [14] could show a mortality rate of 9% for transapical TAVI . The SOURCE Registry representing the largest and most reliable data collection for TAVI using the Edwards Sapien™ valve reports a 30-day mortality of 6.3% for the transfemoral and 10.3% for the transapical group [15] . Differences in mortality were not related to the access site itself but to the differences in periprocedural risk; patients in the transapical group had a significantly higher logistic EuroSCORE and suffered from more comorbidities. More recently, results of the PARTNER (Placement of AoRTic TraNscathetER Valve) trial cohort A, a randomized comparison of TAVI and surgical AVR, showed a surprisingly low overall 30 days mortality rate of 3.4% for TAVI patients in the intention to treat analysis. However, the patients included in this trial were highly selected and 30-day mortality in the treated patient population turned out to be 3.7% for the transfemoral group and 8.7% for the transapical group [16] . Differences in mortality between both approaches reflected the elevated preprocedural risk and a high number of comorbidities in the transapical group.
Compared with these results a 30 days mortality of 7.6% in patients treated transapically with the JenaValve™ system is favourably low and reflects the safety of the system. Although participating centres had large experience with transapical TAVI, there was still a learning curve for use of the new system. This did not relate to an increase in procedural risk but to a reduced procedural success rate of 89.6%. Furthermore, the delivery catheter was modified to improve delivery catheter handling.
Paravalvular leakage remains a concern after TAVI with unknown long-term consequences. Significant AR occurs frequently after TAVI and is associated with increased in-hospital mortality. Although AR is only mild in the majority of patients significant AR ≥2+ can be found in 17-25% of patients [17] [18] [19] . In contrast to currently available valve types, the JenaValve™ prosthesis is able to achieve anatomically correct position by actively attaching to the native leaflets of the valve between the feelers that are placed in the aortic sinuses and the valve stent. This clip mechanism allows for a low stent profile and reduces the amount of paravalvular leakage. In our series, the majority of patients (86.4%) showed no or only mild paravalvular regurgitation (≤1+) while no patient developed significant post-procedural AR (>2+). In addition, the active fixation of the valve on the native leaflets prevents mitral valve impairment. Despite the low stent profile, the valve developed enough radial force to effectively reduce transvalvular gradients from 40.6 ± 15.9 to 10.0 ± 7.2 mmHg and to increase EOA from 0.7 ± 0.2 to 1.7 ± 0.6 cm². Porcine root valves as used in the JenaValve™ prosthesis have been used for >30 years and have proven good long-term durability after surgical valve replacement [20] [21] [22] . The same durability is reported for bovine pericardium as used in the Edwards Sapien™ prosthesis; nevertheless, the heavy forces during valve crimping are known to leave structural damages in the connective tissue of the leaflets [23] . It is as yet unknown if this will negatively influence long-term functionality. Loading of the JenaValve™ prosthesis on the delivery catheter reduces leaflet tissue stress since the valve is only folded into a housing of 32Fr diameter.
While rapid pacing is essential for deployment of balloon-expanded valves, there is no need for this step when implanting a JenaValve™ prosthesis. In the presence of coronary artery disease (CAD) and/or reduced ventricular function rapid pacing may lead to ventricular fibrillation or acute cardiac decompensation. Although 54% of the patients suffered from CAD, none of these events happened during deployment of the JenaValve™ prosthesis. The use of nitinol stents seems to be related to elevated rates of postprocedural AV blocks since pacemaker implantation rates using the Medtronic CoreValve™ are reported to be as high as 30% [24] . Due to the low stent profile and leaflet clip mechanism, the nitinol stent of the JenaValve™ does not reach the left ventricular outflow tract and reduces radial forces in the annulus. In this study, 8 of 66 patients (12.1%) underwent postprocedural pacemaker implantation due to conduction disorders, while new onset of conduction disorders was only detected in 6 of 66 patients (9.1%), a rate that compares favourably to the Medtronic CoreValve™ which also uses a selfexpanding nitinol stent. The distinct features of the JenaValve™ device require manipulation within the aortic root and ascending aorta and may pose a risk for stroke by plaque release. Fortunately, the stroke rate detected in the study was only 3% and did not differ from stroke rates reported for transapical Edwards Sapien™ implantations (2.6%) [14] . Despite some degree of manipulation in the ascending aorta, the atraumatic design of the delivery catheter prevented calcium release from the vessel wall. Antegrade transapical delivery plays an additional role in low stroke rates since retrograde passage of the aortic arch and ascending aorta is avoided. Nevertheless, larger patient numbers are needed to finally assess the neurological risk of the procedure.
Due to limited patient numbers, the urgent question, 'in which patients should the JenaValve™ be favoured over the Edwards Sapien™ valve or vice versa?', cannot be answered today. The low stent profile might be an advantage for the JenaValve™ system in patients with small annuli. In addition, the anatomically correct position in combination with the clip fixation of the native leaflets reduces the risk for coronary obstruction. Therefore, patients with small distances between the annulus and coronary ostia might be better treated with the JenaValve™ device. In contrast patients with extremely calcified valves or very inhomogeneous calcification patterns will most likely benefit more from a balloon expandable rather than self-expandable device. Only with growing experience, will we be able to finally figure out the differences in indications for each valve type.
In conclusion, transapical transcatheter implantation using the second-generation JenaValve™ prosthesis was safe and effective in this multicentre pivotal trial. The valve offers the advantage of anatomically correct feeler-guided positioning by active fixation of the natural valve leaflets thereby reducing the rate of paravalvular leakage. No rapid pacing is required during valve deployment, assuring stable hemodynamic flow during valve implantation. Thirty-day results were promising, with low mortality and event rates. Longer follow-up is needed to evaluate potential benefits in terms of durability and valve performance. The JenaValve™ device offers a new treatment option for transapical TAVI for patients with severe AS and high surgical risk.
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